The Pharma Letter1h
FDA and EMA green light Samsung Bioepis’ Prolia and Xgeva copies
Korean biosimilars company Samsung Bioepis has announced that the US Food and Drug Administration (FDA) and European ...
The Pharma Letter1h
Record Danish pharma exports - but drive for more goes on
Pharmaceuticals continue to be one of the leading Danish exports, according to the latest export figures from Statistics ...
The Pharma Letter3h
GSK’s Penmenvy wins FDA approval
UK pharma major GSK late Friday announced that the US Food and Drug Administration (FDA) has approved Penmenvy (meningococcal ...
The Pharma Letter4h
Pharmsynthez to build a large-scale plant for cancer drug production in Moscow
Pharmsynthez, one of Russia’s largest drugmakers, will build a large-scale plant for the production of anticancer drugs in ...
The Pharma Letter5h
Bambusa Therapeutics raises $90 million in Series A Financing
Boston, USA-based biotech Bambusa Therapeutics, which is developing bispecific antibodies for immunological and inflammatory ...
The Pharma Letter7h
Swedish companies' R&D investments increasing – still at the top in the EU
Swedish companies are increasingly investing in R&D. In 2023, the corporate sector's expenditure on its own R&D amounted to ...
The Pharma Letter7h
Trump’s second term as President: Implications for the FDA and Pharma
Donald Trump marked his inauguration as the 47th President of the USA with a flurry of executive orders and policy rollbacks.
The Pharma Letter7h
FDA nod for first rapid-acting insulin biosimilar
The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart), ...
The Pharma Letter6h
FDA approves rare tumor drug Romvimza
The US Food and Drug Administration (FDA) has approved Romvimza (vimseltinib), from Deciphera Pharmaceuticals, a kinase ...
The Pharma Letter6h
India's cancer market booms with new therapies
India's pharmaceutical market is witnessing a surge in new drug launches, particularly in the oncology segment, fueled by a ...
The Pharma Letter1h
Formycon drops development of biosimilar FYB206
Germany’s Formycon has decided today to prematurely terminate the Phase III trial (Lotus) for its biosimilar candidate FYB206, with the news pushing its share price down nearly 32% at 34.00 euros as ...
The Pharma Letter3h
Investors unsure on Corbus data for potential Padcev rival
Corbus earlier announced the presentation of data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 (SYS6002) at the 2025 American Society of Clinical Oncology ...